Cytosorbents Corp Financials
Cytosorbents Corp (CTSO) reported $37.2M in revenue over the twelve months to Jun 30, 2026, up 3.1% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Margin recovery is narrowing losses, yet the operating model still relies on external financing to fund ongoing cash needs.
From FY2024 to FY2025, revenue rose to$37.1M while gross margin widened to71.5% . That combination narrowed the operating loss from$16.5M to$14.7M , yet the added gross profit still did not reach operating break-even.
Operating cash flow improved to
External funding remains part of the model: financing cash flow was
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Cytosorbents Corp's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Not available for Cytosorbents Corp, and counted as zero in the overall score.
Cytosorbents Corp scores -9.52, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($21.4M) relative to total liabilities ($38.3M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Cytosorbents Corp passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
Cytosorbents Corp reported a net loss of $8.2M while operations used $12.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Cytosorbents Corp generated $37.1M in revenue in fiscal year 2025. This represents an increase of 4.1% from the prior year.
Cytosorbents Corp's EBITDA was -$13.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 10.6% from the prior year.
Cytosorbents Corp reported -$8.2M in net income in fiscal year 2025. This represents an increase of 60.4% from the prior year.
Cytosorbents Corp earned -$0.13 per diluted share (EPS) in fiscal year 2025. This represents an increase of 65.8% from the prior year.
Cash & Balance Sheet
Cytosorbents Corp recorded an outflow of $12.5M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 14.8% from the prior year.
Cytosorbents Corp held $6.2M in cash against $16.7M in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Cytosorbents Corp's gross margin was 71.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 1.6 percentage points from the prior year.
Cytosorbents Corp's operating margin was -39.8% in fiscal year 2025, reflecting core business profitability. This is up 6.4 percentage points from the prior year.
Cytosorbents Corp's net profit margin was -22.1% in fiscal year 2025, showing the share of revenue converted to profit. This is up 36.1 percentage points from the prior year.
Cytosorbents Corp's ROE was -138.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 47.7 percentage points from the prior year.
Capital Allocation
Cytosorbents Corp invested $164K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 42.3% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
CTSO Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.6M+8.7% | $8.9M-4.0% | $9.2M-2.6% | $9.5M-1.4% | $9.6M+10.2% | $8.7M-4.6% | $9.2M+6.2% | $8.6M |
| Cost of Revenue | $2.6M-5.5% | $2.7M+12.5% | $2.4M-13.8% | $2.8M+0.6% | $2.8M+11.2% | $2.5M-13.0% | $2.9M-13.7% | $3.4M |
| Gross Profit | $7.0M+15.0% | $6.1M-9.9% | $6.8M+2.1% | $6.7M-2.2% | $6.8M+9.8% | $6.2M-0.8% | $6.3M+19.0% | $5.3M |
| R&D Expenses | $1.5M+41.8% | $1.0M | N/A | N/A | $1.3M-24.1% | $1.7M | N/A | $1.9M |
| SG&A Expenses | $8.0M-2.3% | $8.1M-13.6% | $9.4M+9.6% | $8.6M-6.1% | $9.2M+8.7% | $8.4M+10.4% | $7.6M-7.6% | $8.3M |
| Operating Income | -$2.6M+13.3% | -$3.0M+30.6% | -$4.4M-53.2% | -$2.9M+20.8% | -$3.6M+7.0% | -$3.9M-14.5% | -$3.4M+29.7% | -$4.8M |
| Income Tax | $0 | $0 | $0+100.0% | -$401K | $0 | $0 | N/A | $0 |
| Net Income | -$4.4M+13.9% | -$5.1M+6.7% | -$5.5M-73.4% | -$3.2M-262.8% | $1.9M+231.6% | -$1.5M+80.5% | -$7.6M-173.4% | -$2.8M |
| EPS (Diluted) | -$0.07+12.5% | -$0.08+11.1% | -$0.09-80.0% | -$0.05-266.7% | $0.03+250.0% | -$0.02+85.7% | -$0.14-180.0% | -$0.05 |
Not reported in any period shown, so not listed: Interest Expense.
CTSO Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $38.0M-6.4% | $40.6M-8.2% | $44.2M-3.4% | $45.8M-4.7% | $48.0M-5.5% | $50.8M+7.2% | $47.4M-0.9% | $47.8M |
| Current Assets | $15.7M-11.4% | $17.8M-13.9% | $20.6M-3.2% | $21.3M-7.3% | $23.0M-9.5% | $25.4M+17.6% | $21.6M+30.2% | $16.6M |
| Cash & Equivalents | $4.4M-8.3% | $4.8M-23.0% | $6.2M-17.1% | $7.5M-26.1% | $10.2M-11.9% | $11.6M+253.3% | $3.3M-42.3% | $5.7M |
| Inventory | $3.7M-17.7% | $4.5M-15.1% | $5.3M+32.0% | $4.0M+7.9% | $3.7M+22.9% | $3.0M+10.4% | $2.7M-15.8% | $3.2M |
| Accounts Receivable | $6.8M-5.1% | $7.2M-5.3% | $7.5M+1.7% | $7.4M-4.1% | $7.7M+0.9% | $7.7M+4.8% | $7.3M+10.4% | $6.6M |
| Total Liabilities | $38.7M+0.9% | $38.4M+0.2% | $38.3M+4.2% | $36.7M+0.9% | $36.4M+0.5% | $36.2M-0.1% | $36.3M+4.6% | $34.7M |
| Current Liabilities | $24.0M+47.4% | $16.3M+67.9% | $9.7M-4.0% | $10.1M+2.7% | $9.8M+1.1% | $9.7M-0.9% | $9.8M+18.6% | $8.3M |
| Long-Term Debt | $3.1M-70.0% | $10.3M-38.1% | $16.7M+14.4% | $14.6M+1.3% | $14.4M+1.3% | $14.2M+1.4% | $14.0M+1.4% | $13.8M |
| Total Equity | -$751K-134.2% | $2.2M-62.8% | $5.9M-34.6% | $9.0M-22.1% | $11.6M-20.3% | $14.5M+30.9% | $11.1M-17.0% | $13.4M |
| Retained Earnings | -$321.8M-1.4% | -$317.3M-1.6% | -$312.2M-1.8% | -$306.7M-1.0% | -$303.5M+0.6% | -$305.5M-0.5% | -$304.0M-2.6% | -$296.4M |
Not reported in any period shown, so not listed: Goodwill.
CTSO Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$583K+49.8% | -$1.2M+75.9% | -$4.8M-87.2% | -$2.6M-70.8% | -$1.5M+56.5% | -$3.5M-48.1% | -$2.3M+5.0% | -$2.5M |
| Capital Expenditures | $14K+27.3% | $11K-89.8% | $108K+535.3% | $17K-54.1% | $37K+1750.0% | $2K-97.1% | $69K-54.6% | $152K |
| Free Cash Flow | -$597K+49.1% | -$1.2M+76.2% | -$4.9M-90.2% | -$2.6M-67.8% | -$1.5M+55.4% | -$3.5M-43.9% | -$2.4M+7.8% | -$2.6M |
| Investing Cash Flow | $7K+115.2% | -$46K+84.2% | -$291K-629.1% | $55K+141.7% | -$132K-180.9% | -$47K+62.1% | -$124K+58.5% | -$299K |
| Financing Cash Flow | N/A | N/A | $2.5M | $0 | $0-100.0% | $6.8M+3990.4% | $167K+268.7% | -$99K |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
CTSO Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 73.2%+4.0pp | 69.2%-4.5pp | 73.7%+3.4pp | 70.3%-0.6pp | 70.9%-0.3pp | 71.1%+2.8pp | 68.3%+7.3pp | 61.0% |
| Operating Margin | -27.4%+7.0pp | -34.3%+13.1pp | -47.5%-17.3pp | -30.2%+7.4pp | -37.6%+7.0pp | -44.5%-7.4pp | -37.1%+19.0pp | -56.1% |
| Net Margin | -45.9%+12.0pp | -57.9%+1.6pp | -59.5%-26.1pp | -33.4%-53.7pp | 20.3%+37.2pp | -17.0%+65.8pp | -82.7%-50.6pp | -32.1% |
| Return on Equity | N/A | -233.8%-140.7pp | -93.1%-58.0pp | -35.1%-51.9pp | 16.8%+27.0pp | -10.2%+58.0pp | -68.1%-47.5pp | -20.7% |
| Return on Assets | -11.6%+1.0pp | -12.6%-0.2pp | -12.4%-5.5pp | -6.9%-11.0pp | 4.1%+7.0pp | -2.9%+13.1pp | -16.0%-10.2pp | -5.8% |
| Current Ratio | 0.66-0.4x | 1.09-1.0x | 2.130.0x | 2.11-0.2x | 2.34-0.3x | 2.61+0.4x | 2.20+0.2x | 2.00 |
| Debt-to-Equity | N/A | 4.70+1.9x | 2.82+1.2x | 1.61+0.4x | 1.24+0.3x | 0.98-0.3x | 1.26+0.2x | 1.03 |
| FCF Margin | -6.2%+7.0pp | -13.2%+40.2pp | -53.4%-26.1pp | -27.4%-11.3pp | -16.1%+23.7pp | -39.7%-13.4pp | -26.3%+4.0pp | -30.4% |
Similar Companies
Where Cytosorbents Corp Ranks
Frequently Asked Questions
What is Cytosorbents Corp's annual revenue?
Cytosorbents Corp (CTSO) reported $37.1M in total revenue for fiscal year 2025. This represents a 4.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Cytosorbents Corp's revenue growing?
Cytosorbents Corp (CTSO) revenue grew by 4.1% year-over-year, from $35.6M to $37.1M in fiscal year 2025.
Is Cytosorbents Corp profitable?
No, Cytosorbents Corp (CTSO) reported a net income of -$8.2M in fiscal year 2025, with a net profit margin of -22.1%.
What is Cytosorbents Corp's EBITDA?
Cytosorbents Corp (CTSO) had EBITDA of -$13.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Cytosorbents Corp have?
As of fiscal year 2025, Cytosorbents Corp (CTSO) had $6.2M in cash and equivalents against $16.7M in long-term debt.
What is Cytosorbents Corp's gross margin?
Cytosorbents Corp (CTSO) had a gross margin of 71.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Cytosorbents Corp's operating margin?
Cytosorbents Corp (CTSO) had an operating margin of -39.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Cytosorbents Corp's net profit margin?
Cytosorbents Corp (CTSO) had a net profit margin of -22.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Cytosorbents Corp's return on equity (ROE)?
Cytosorbents Corp (CTSO) has a return on equity of -138.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Cytosorbents Corp's free cash flow?
Cytosorbents Corp (CTSO) recorded an outflow of $12.5M in free cash flow during fiscal year 2025. This represents a 14.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Cytosorbents Corp's operating cash flow?
Cytosorbents Corp (CTSO) recorded an outflow of $12.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Cytosorbents Corp's total assets?
Cytosorbents Corp (CTSO) had $44.2M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Cytosorbents Corp's capital expenditures?
Cytosorbents Corp (CTSO) invested $164K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Cytosorbents Corp's current ratio?
Cytosorbents Corp (CTSO) had a current ratio of 2.13 as of fiscal year 2025, which is generally considered healthy.
What is Cytosorbents Corp's debt-to-equity ratio?
Cytosorbents Corp (CTSO) had a debt-to-equity ratio of 2.82 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Cytosorbents Corp's return on assets (ROA)?
Cytosorbents Corp (CTSO) had a return on assets of -18.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Cytosorbents Corp's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Cytosorbents Corp (CTSO) held $6.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $12.4M over that year. Dividing the one by the other, the reported balance equals about 6 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Cytosorbents Corp's Altman Z-Score?
Cytosorbents Corp (CTSO) has an Altman Z-Score of -9.52, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Cytosorbents Corp's Piotroski F-Score?
Cytosorbents Corp (CTSO) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Cytosorbents Corp's earnings high quality?
Cytosorbents Corp (CTSO) reported a net loss of $8.2M while operations used $12.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Cytosorbents Corp?
Cytosorbents Corp (CTSO) scores 37 out of 100 on our Financial Health Score, indicating weak standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.